New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab
- 1 December 2020
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1874 (2) , 188448
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Combined targeting of HER2 and VEGFR2 for effective treatment ofHER2-amplified breast cancer brain metastasesProceedings of the National Academy of Sciences, 2012
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancerCancer Chemotherapy and Pharmacology, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- A novel fully human antitumour immunoRNase targeting ErbB2-positive tumoursBritish Journal of Cancer, 2011
- Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteinsCell Death & Disease, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translationThe EMBO Journal, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell, 2004